Novo Nordisk (NVO), the maker of popular obesity/diabetes medications Ozempic and Wegovy, warned Thursday that the Trump ...
Zacks Investment Research on MSN55m
Novo Nordisk Lowers Wegovy Costs for Cash-Pay Patients, Stock Up 4%Novo Nordisk NVO announced that it is launching a new direct-to-patient online pharmacy called NovoCare, which will offer its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback